We are delighted to announce that endocrinologist and physician scientist, Professor Alicia Jenkins, will join the Institute in January 2023 to lead a new Diabetes and Vascular Medicine Laboratory.
Professor Jenkins has a particular interest in type 1 and type 2 diabetes and their associated complications, as well as vascular medicine, biomarkers and the use of technology in healthcare.
Most recently, she was Academic Head of Diabetes at the NHMRC Clinical Trials Center in Sydney, where she was responsible for the design and conduct of major national and international diabetes clinical studies and a biomarker laboratory. She has also served as Professor of Diabetes and Vascular Medicine at the University of Sydney since 2013.
Professor Jenkins trained in medicine and research in Australia, the UK, Ireland and the USA. After 13 years at the University of Melbourne and St Vincent’s Hospital Melbourne, she joined the University of Sydney in 2012. She continues her clinical work in type 1 diabetes at St. Vincent’s Hospital and the University of Melbourne and will begin clinical work at Baker-related clinics in 2023.
For 23 years she led a multidisciplinary team in Australia, with collaborative cardiometabolic research in the US, Europe, UK and the Western Pacific region. His interests lie in the prediction and prevention and underlying mechanisms of diabetes and vascular disease complications and the use of advanced technologies in diabetes care, including insulin pumps, continuous blood glucose monitors and digital health.
Professor Jenkins holds a number of fellowships from national and international funding bodies. She has also won several major awards, including the 2019 Kellion Award from the Australian Diabetes Society for Outstanding Contribution to Diabetes Research and Clinical Care, an Australian Museum Eureka Award for Medical Research, and the 2022 RACP International Medal for his work in underprivileged countries.
His clinical practice focuses on type 1 diabetes care from youth to old age, including insulin pump and glucose sensor use, and is complementary to his research and training.
She sits on numerous committees that develop clinical practice guidelines and position statements. She has served on the Australian Diabetes Council and now represents Australia at the International Diabetes Federation and is President of Insulin for Life Global as well as the Australian Chapter. She is co-director of the Australian Cardiovascular Alliance (ACvA) Precision Medicine Flagship (with Professor Peter Meikle of the Baker Institute) and plays a key role in the Australian Center for Accelerating Diabetes Innovations (ACADI), the Diabetes Technology Research Group (DTRG) and the JDRF Global Center of Excellence in Diabetes Research.
Professor Jenkins is also recognized for her teaching, mentoring and advocacy work.
She founded the Global Elective Medical Student program in 2018 which links clinical schools, initially in Hong Kong, Australia, Europe and the United States, and aims to improve the education of doctors by offering elective courses that include at the both clinical skills training and clinical or community research. commitment.
She is also an active collaborator of the “Life for a Child” program and has founded an advocacy group which advocates, in particular in collaboration with the United Nations Special Rapporteur for the Right to Health, in favor of equitable access to care. diabetes.
Professor Jenkins says key projects she will focus on include the FAME-1 trial of fenofibrate in diabetic retinopathy in adults with type 1 diabetes, insulin pump and sensor studies and related trials to the cardiometabolic health of Indigenous Australians.
Director of the Baker Institute, Professor Tom Marwick, says we have a long and proud history of diabetes research and we are delighted to have another senior diabetes researcher join our institute and help drive this pioneering work.
“Professor Jenkins has an excellent scientific background, numerous collaborations and has developed initiatives ranging from teaching to advocacy that align with the Institute’s focus on research translation and equity. in health.